title: A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
abstract: New approaches to breast cancer treatment have enhanced clinical outcomes and patient care. These approaches include advances in breast irradiation and hormonal and systemic adjuvant therapies. In addition to the identification of new drug targets and targeted therapeutics (eg, trastuzumab), there is renewed re-emphasis in the development of biomarkers for the prediction of response to therapy. One example is the pharmacogenetics of tamoxifen metabolism and the individualization of hormonal therapy. The current treatment of breast cancer continues to evolve rapidly, with new scientific and clinical achievements constantly changing the standard of care and leading to substantial reductions in breast cancer mortality. The goal of this article is to provide clinicians who care for women with breast cancer a multidisciplinary, state-of-the art approach to the treatment of these patients.
authors.affiliation: Division of General Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. pruthi.sandhya@mayo.edu
authors.forename: Sandhya
authors.initials: S
authors.lastname: Pruthi
authors.forename: Judy C
authors.initials: JC
authors.lastname: Boughey
authors.forename: Kathleen R
authors.initials: KR
authors.lastname: Brandt
authors.forename: Amy C
authors.initials: AC
authors.lastname: Degnim
authors.forename: Grace K
authors.initials: GK
authors.lastname: Dy
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Goetz
authors.forename: Edith A
authors.initials: EA
authors.lastname: Perez
authors.forename: Carol A
authors.initials: CA
authors.lastname: Reynolds
authors.forename: Paula J
authors.initials: PJ
authors.lastname: Schomberg
authors.forename: James N
authors.initials: JN
authors.lastname: Ingle
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001918:Brachytherapy; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D018734:Genes, erbB-2 / Q000187:drug effects; D006801:Humans; D000077341:Lapatinib; D008297:Male; D008408:Mastectomy; D010597:Pharmacogenetics; D011799:Quinazolines / Q000494:pharmacology; D011829:Radiation Dosage; D013629:Tamoxifen / Q000627:therapeutic use; D000068878:Trastuzumab; D016896:Treatment Outcome